Carotuximab, also known as TRC105 or DE-122, represents a novel antibody-drug conjugate therapeutic currently being studied for treating various malignant conditions. This specific molecule targets a defined antigen, https://deaconyxkq175206.wikicommunications.com/7519131/carotuximab_trc105_de_122_a_deep_dive